YIM Session 4: Approach Considerations and Treatment Options in CLL

Co-Chair(s)

• 

  Kerry Rogers, MD

  Associate Professor
  The Ohio State University
  Columbus, OH, United States
• 

  Philip Thompson, MBBS (Hons)

  Consultant Haematologist
  Department of Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre and The Sir Peter MaCallum Department of Clinical Oncology, University of Melbourne
  Melbourne, Victoria, Australia

Presentations:

• 12:30 PM – 12:40 PM EDT

  A Study of Frontline Therapy in Adults Aged 80+ Years with Chronic Lymphocytic Leukemia (CLL)
  

  Primary Author; Presenting Author: Mazie Tsang, MD, MAS, MS – Mayo Clinic Arizona

  Co-Author: Paul J. Hampel, MD – Mayo Clinic

  Co-Author: Kari G. Rabe, MS – Mayo Clinic

  Co-Author: Wei Ding, MD, PhD – Mayo Clinic

  Co-Author: Jose F. Leis, MD, PhD – Mayo Clinic

  Co-Author: Saad S. Kenderian, MB, ChB – Mayo Clinic

  Co-Author: Yucai Wang, MD, PhD – Mayo Clinic

  Co-Author: Eli Muchtar, MD – Mayo Clinic

  Co-Author: Amber Koehler, PA-C, MS – Division of Hematology, Mayo Clinic

  Co-Author: Curtis A. Hanson, MD – Mayo Clinic

  Co-Author: Min Shi, MD, PhD – Mayo Clinic

  Co-Author: Susan L. Slager, PhD – Mayo Clinic

  Co-Author: Neil E. Kay, MD – Mayo Clinic

  Co-Author: Sameer A. Parikh, M.B.B.S. – Mayo Clinic
• 12:40 PM – 12:50 PM EDT

  Clinical outcomes in patients with chronic lymphocytic leukemia (CLL) treated with venetoclax-based regimens
  

  Primary Author; Presenting Author: Paul J. Hampel, MD – Mayo Clinic

  Co-Author: Kari G. Rabe, MS – Mayo Clinic

  Co-Author: Yucai Wang, MD, PhD – Mayo Clinic

  Co-Author: Saad S. Kenderian, MB, ChB – Mayo Clinic

  Co-Author: Wei Ding, MD, PhD – Mayo Clinic

  Co-Author: Eli Muchtar, MD – Mayo Clinic

  Co-Author: Jose F. Leis, MD, PhD – Mayo Clinic

  Co-Author: Amber Koehler, PA-C, MS – Division of Hematology, Mayo Clinic

  Co-Author: Mazie Tsang, MD, MAS, MS – Mayo Clinic Arizona

  Co-Author: Ricardo Parrondo, MD – Mayo Clinic

  Co-Author: Rachel Bubik, PharmD – Department of Pharmacy, Mayo Clinic

  Co-Author: Susan M. Schwager, BA – Mayo Clinic

  Co-Author: Curtis A. Hanson, MD – Mayo Clinic

  Co-Author: Esteban Braggio, PhD – Mayo Clinic

  Co-Author: Susan L. Slager, PhD – Mayo Clinic

  Co-Author: Min Shi, MD, PhD – Mayo Clinic

  Co-Author: Daniel L. Van Dyke, PhD – Mayo Clinic

  Co-Author: Timothy G. Call, MD – Mayo Clinic

  Co-Author: Neil E. Kay, MD – Mayo Clinic

  Co-Author: Sameer A. Parikh, MBBS – Mayo Clinic
• 12:50 PM – 1:00 PM EDT

  Explainable Machine Learning to Identify Chronic Lymphocytic Leukemia Based on Gut Microbiome Data
  

  Primary Author: Tereza Faitova, N/A – Rigshospitalet, Copenhagen University Hospital

  Co-Author: Ramtin Zargari Marandi, N/A

  Co-Author; Presenting Author: Carsten Utoft Niemann, MD, PhD – Department of Hematology, Copenhagen University Hospital Rigshospitalet, Denmark; Hematology Research Group, Danish Cancer Institute Research Center, Denmark; Department of Clinical Medicine, Copenhagen University
• 1:00 PM – 1:10 PM EDT

  Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemia (CLL)
  

  Primary Author; Presenting Author: Kiyomi Mashima, MD, PhD – Dana-Farber Cancer Institute

  Co-Author: Yanan Kuang, PhD – Dana-Farber Cancer Institute

  Co-Author: Stacey M. Fernandes, BS – Dana-Farber Cancer Institute

  Co-Author: Samantha Shupe, BS – Dana-Farber Cancer Institute

  Co-Author: Rayan Fardoun, BS – Dana-Farber Cancer Institute

  Co-Author: Mariia Mikhaleva, MD – Dana-Farber Cancer Institute

  Co-Author: Aishath Naeem, PhD – Dana-Farber Cancer Institute

  Co-Author: Benjamin Hanna – Dana-Farber Cancer Institute

  Co-Author: Cloud P. Paweletz, PhD – Dana-Farber Cancer Institute

  Co-Author: Matthew S. Davids, MD, MMSc – Dana-Farber Cancer Institute (DFCI)

  Co-Author: Jennifer R. Brown, MD, PhD – Department of Medical Oncology, Dana-Farber Cancer Institute (DFCI); Department of Medicine, Harvard Medical School (HMS)
• 1:10 PM – 1:20 PM EDT

  Sensitive monitoring of sequential targeted therapy resistance in relapsed/therapy refractory chronic lymphocytic leukemia
  

  Primary Author; Presenting Author: Lili Kotmayer, MD, PhD – HCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University

  Co-Author: Tamas Laszlo, MD

  Co-Author: Donat Alpar, PhD

  Co-Author: Csaba Bödör, PhD, DSc – Semmelweis University / HCEMM
• 1:20 PM – 1:30 PM EDT

  Single center report on cohort of patients relapsed on Bruton Tyrosine Kinase inhibitors (BTKi)
  

  Primary Author; Presenting Author: Huayuan Zhu, MD – the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital

  Co-Author: Luomengjia Dai, Dr – Department of Hematology, the First Affiliated Hospital of Nanjing Medical University

  Co-Author: Yeqin Sha, Dr – Department of Hematology, the First Affiliated Hospital of Nanjing Medical University

  Co-Author: Ziyuan Zhou, Dr – Department of Hematology, the First Affiliated Hospital of Nanjing Medical University

  Co-Author: Siqi Qian, Dr – Department of Hematology, the First Affiliated Hospital of Nanjing Medical University

  Co-Author: Xiao Lu, Dr – Department of Hematology, the First Affiliated Hospital of Nanjing Medical University

  Co-Author: Tonglu Qiu, Dr – Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital

  Co-Author: Yi Miao, Dr – Department of Hematology, the First Affiliated Hospital of Nanjing Medical University

  Co-Author: Shuchao Qin, Dr – Department of Hematology, the First Affiliated Hospital of Nanjing Medical University

  Co-Author: Yi Xia, MD – the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital

  Co-Author: Lei Fan, Dr – Department of Hematology, the First Affiliated Hospital of Nanjing Medical University

  Co-Author: Wei Xu, MD, PhD – Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital

  Co-Author: Jianyong Li, MD, PhD – Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
• 1:30 PM – 1:40 PM EDT

  Time-limited venetoclax-rituximab is effective for patients with Bruton tyrosine kinase exposed chronic lymphocytic leukaemia, but durable treatment-free remissions are uncommon
  

  Primary Author; Presenting Author: Thomas E. Lew, MBBS BMedSci(Hons) – Peter MacCallum Cancer Centre and Royal Melbourne Hospital

  Co-Author: Rory Bennett, MBChB – Department of Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre

  Co-Author: Victor S. Lin, MBBS – Royal Melbourne Hospital

  Co-Author: Ashley Whitechurch, RN – Peter MacCallum Cancer Centre and Royal Melbourne Hospital

  Co-Author: Sasanka M. Handunnetti, MBBS, PhD – Princess Alexandra Hospital

  Co-Author: Paula Marlton, MBBS – Princess Alexandra Hospital

  Co-Author: Yandong Shen, PhD – Royal North Shore Hospital

  Co-Author: Stephen Mulligan, MBBS, PhD – Royal North Shore Hospital

  Co-Author: Joshua Casan, MBBS, PhD – Peter MacCallum Cancer Centre and Royal Melbourne Hospital

  Co-Author: Piers blombery, MBBS, PhD – Peter MacCallum Cancer Centre

  Co-Author: Constantine S. Tam, MD, MBBS – Alfred Hospital and Monash University

  Co-Author: Andrew W. Roberts, MBBS, PhD – Royal Melbourne Hospital & Peter MacCallum Cancer Centre

  Co-Author: John F. Seymour, MBBS, FRACP, PhD – Royal Melbourne Hospital, Peter MacCallum Cancer Centre and University of Melbourne

  Co-Author: Philip Thompson, MBBS (Hons) – Department of Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre and The Sir Peter MaCallum Department of Clinical Oncology, University of Melbourne

  Co-Author: Mary Ann Anderson, MBBS, PhD – Department of Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre
• 1:40 PM – 1:45 PM EDT

  Association between hypertension and overall survival in chronic lymphocytic leukemia
  

  Primary Author: Noomi Vainer, PhD – Department of Hematology, Copenhagen University Hospital Rigshospitalet, Denmark; Hematology Research Group, Danish Cancer Institute Research Center

  Co-Author: Christian Brieghel, MD, PhD – Department of Hematology, Copenhagen University Hospital Rigshospitalet

  Co-Author: Henrik Hjalgrim, Professor, MD, Ph.D., DMSc – Department of Hematology, Copenhagen University Hospital Rigshospitalet, Denmark; Hematology Research Group, Danish Cancer Institute Research Center, Denmark; Department of Epidemiology Research, Statens Serum Institut; Department of Clinical Medicine, Copenhagen University, Denmark.

  Co-Author: Carsten Utoft Niemann, MD, PhD – Department of Hematology, Copenhagen University Hospital Rigshospitalet, Denmark; Hematology Research Group, Danish Cancer Institute Research Center, Denmark; Department of Clinical Medicine, Copenhagen University

  Co-Author; Presenting Author: Emelie Hamotal Curovic Rotbain, MD, PhD – Department of Hematology, Copenhagen University Hospital Rigshospitalet, Denmark;
  Hematology Research Group, Danish Cancer Institute Research Center
• 1:45 PM – 1:50 PM EDT

  Changes in immune cell numbers and profile during long-term zanubrutinib treatment in treatment-naïve and relapsed/refractory patients with chronic lymphocytic leukemia
  

  Primary Author; Presenting Author: Maria L. Andersson, MD – Department of oncology-pathology, Karolinska Institutet, Stockholm, Sweden; Lymphoma Unit, Karolinska University Hospital

  Co-Author: Tom Mulder, MD, PhD – Department of oncology-pathology, Karolinska Institutet

  Co-Author: Kia Heimersson, BMS – Department of oncology-pathology, Karolinska Institutet

  Co-Author: Sonja Sönnert-Husa, N/A – Center for clinical cancer studies, Karolinska University Hospital

  Co-Author: Annika Giertz, N/A – Center for clinical cancer studies, Karolinska University Hospital

  Co-Author: Claes Karlsson, MD, PhD – Department of oncology-pathology, Karolinska Institutet, Stockholm, Sweden; Lymphoma Unit, Karolinska University Hospital

  Co-Author: Jeanette Lundin, Assoc. Professor, MD, PhD – Department of oncology-pathology, Karolinska Institutet, Stockholm, Sweden; Lymphoma Unit, Karolinska University Hospital

  Co-Author: Lotta Hansson, Assoc. Professor, MD, PhD – Department of oncology-pathology, Karolinska Institutet, Stockholm, Sweden; Lymphoma Unit, Karolinska University Hospital

  Co-Author: Anders Österborg, Professor, MD, PhD – Department of oncology-pathology, Karolinska Institutet, Stockholm, Sweden; Lymphoma Unit, Karolinska University Hospital

  Co-Author: Marzia Palma, MD, PhD – Department of oncology-pathology, Karolinska Institutet, Stockholm, Sweden; Lymphoma Unit, Karolinska University Hospital
• 1:50 PM – 1:55 PM EDT

  Impact of COVID-19 in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a possible role of the association to anti-CD20 antibody? A multicentre SEIFEM study.
  

  Primary Author; Presenting Author: Francesco Autore, MD, PhD – Fondazione Policlinico Universitario A. Gemelli IRCCS

  Co-Author: Andrea Visentin, MD – Università degli Studi di Padova

  Co-Author: Marina Deodato, MD – ASST Grande Ospedale Metropolitano Niguarda

  Co-Author: Candida Vitale, MD, PhD – 1 Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Via Genova 3,10126, Torino, Italy
  2 Department of Molecular Biotechnology and Health Sciences, University of Torino
  

  Co-Author: Eugenio Galli, MD, PhD – Fondazione Policlinico Universitario Agostino Gemelli IRCCS

  Co-Author: Alberto Fresa, MD – Fondazione Policlinico Universitario Agostino Gemelli IRCCS

  Co-Author: Rita Fazzi, MD – Azienda Ospedaliera Universitaria Pisana

  Co-Author: Alessandro Sanna, MD – Azienda Ospedaliera Universitaria di Careggi

  Co-Author: Jacopo Olivieri, MD – Clinica Ematologia di Udine

  Co-Author: Ilaria Scortechini, MD – Azienda ospedaliero Universitaria delle Marche

  Co-Author: Maria Ilaria del Principe, MD – Università degli studi di Roma Tor Vergata

  Co-Author: Paolo Sportoletti, MD – A.O. Santa Maria della Misericordia di Perugia

  Co-Author: Luana Schiattone, MD – Presidio Ospedaliero S.Spirito di Pescara

  Co-Author: Nilla Maschio, MD – Istituto Oncologico Veneto IOV-IRCCS

  Co-Author: Davide Facchinelli, MD – Ospedale San Bortolo

  Co-Author: Marta Coscia, MD, PhD – Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Via Genova 3,10126, Torino, Italy2 Department of Molecular Biotechnology and Health Sciences, University of Torino

  Co-Author: Alessandra Tedeschi, MD – Department of Hematology, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

  Co-Author: Livio Trentin, MD – Università degli Studi di Padova

  Co-Author: Idanna Innocenti, MD – Section of Hematology, Department of Radiological and Hematological Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS

  Co-Author: Anna Candoni, MD – Università degli Studi di Modena e Reggio Emilia

  Co-Author: Alessandro busca, MD – A.O.U. Città della Salute e della Scienza di Torino

  Co-Author: Livio Pagano, MD – Fondazione Policlinico Universitario A. Gemelli IRCCS

  Co-Author: Luca Laurenti, MD – Section of Hematology, Department of Radiological and Hematological Sciences, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
• 1:55 PM – 2:05 PM EDT

  Session 4: Panel Discussion